Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer’s (PFE) experimental MASH therapy ervogastat. Read more here.
The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...
Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback